Clinical significance of caspase‐3 expression in pathologic‐stage I, nonsmall‐cell lung cancer

Caspase‐3 is a cysteine protease that plays an important role in the process of apoptotic cell death. Whereas many studies on the clinical significance of apoptosis in the therapy of malignant tumors have been reported, little has been studied clinically on caspase‐3. In the present study, the clinical significance of caspase‐3 expression in resected nonsmall‐cell lung cancer (NSCLC) and its correlation with incidence of apoptosis were examined. A total of 118 consecutive patients who had undergone complete resection for pathologic Stage I NSCLC were retrospectively reviewed. Caspase‐3 expression was examined immunohistochemically using a polyclonal antibody that recognized uncleaved caspase‐3. The 5‐year survival rate for patients with strong expression of caspase‐3 (66.6%) was significantly lower than that for patients with weak expression (82.1%, P = 0.021). Expression of caspase‐3 was not correlated with incidence of apoptosis, proliferative activity, or p53 status. Multivariate analysis confirmed that strong expression of caspase‐3 was a significant factor to predict poor prognosis. These results suggest that enhanced expression of “uncleaved” caspase‐3, that is, inactivated caspase‐3, was correlated with poor prognosis in resected NSCLC. © 2002 Wiley‐Liss, Inc.

[1]  M. Volm,et al.  Relationship between the expression of caspase-3 and the clinical outcome of patients with non-small cell lung cancer. , 2000, Anticancer research.

[2]  R. Gascoyne,et al.  Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. , 1997, Cancer research.

[3]  W. Travis,et al.  Histological Classification of Lung and Pleural Tumours , 1999 .

[4]  C. Winterford,et al.  Apoptosis. Its significance in cancer and cancer Therapy , 1994, Cancer.

[5]  M. Su,et al.  High levels of expression and nuclear localization of interleukin-1 beta converting enzyme (ICE) and CPP32 in favorable human neuroblastomas. , 1997, Cancer research.

[6]  H. Wada,et al.  Time trends and survival after operations for primary lung cancer from 1976 through 1990. , 1996, The Journal of thoracic and cardiovascular surgery.

[7]  B. Zhivotovsky,et al.  Detection of pro‐caspase‐3 in cytosol and mitochondria of various tissues , 1998, FEBS letters.

[8]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[9]  H. Wada,et al.  Lewis Y antigen expression and postoperative survival in non-small cell lung cancer. , 1998, The Annals of thoracic surgery.

[10]  Sharad Kumar,et al.  ICE-like proteases in apoptosis. , 1995, Trends in biochemical sciences.

[11]  H. Wada,et al.  p53 Status Predicts the Efficacy of Postoperative Oral Administration of Tegafur for Completely Resected Non‐small Cell Lung Cancer† , 1999, Japanese journal of cancer research : Gann.

[12]  A. Schmitz,et al.  Activation of Membrane-associated Procaspase-3 Is Regulated by Bcl-2 , 1999, The Journal of cell biology.

[13]  N. Thornberry,et al.  Caspases: killer proteases. , 1997, Trends in biochemical sciences.

[14]  M. Volm,et al.  Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival , 2000, British Journal of Cancer.

[15]  M. Volm,et al.  Prognostic relevance of c-Myc and caspase-3 for patients with non-small cell lung cancer. , 2000, Oncology reports.

[16]  S. Saito,et al.  Detection of Apoptosis and Expression of Apoptosis‐associated Proteins as Early Predictors of Prognosis after Irradiation Therapy in Stage IIIb Uterine Cervical Cancer , 2000, Japanese journal of cancer research : Gann.

[17]  B. Barres,et al.  Programmed cell death and the control of cell survival: lessons from the nervous system. , 1993, Science.

[18]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[19]  Seamus J. Martin,et al.  Protease activation during apoptosis: Death by a thousand cuts? , 1995, Cell.

[20]  N. Thornberry,et al.  The Caspase-3 Precursor Has a Cytosolic and Mitochondrial Distribution: Implications for Apoptotic Signaling , 1998, The Journal of cell biology.

[21]  F. Pearson.  Non-small cell lung cancer: role of surgery for stages I-III. , 1999, Chest.

[22]  P. Thall,et al.  Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. , 1998, Blood.

[23]  P. Thall,et al.  Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  Xiaodong Wang,et al.  Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c–Dependent Activation of Caspase-3 , 1997, Cell.

[25]  H. Wada,et al.  Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  I. Lauder,et al.  Immunohistochemical localization of caspase-3 correlates with clinical outcome in B-cell diffuse large-cell lymphoma. , 1999, Cancer research.

[27]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.